Andrea Gillis

Dr. Andrea Gillis


Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 August 2023 in The Journal of Clinical Endocrinology & Metabolism
Verified
Journal Article
Closed access
PDF file
AGAndrea Gillis
Andrea Gillis
HCHerbert Chen
Herbert Chen
TWTracy S Wang
Tracy S Wang
SDSophie Dream
Sophie Dream
Context: There are differences in diagnosis, treatment, and outcomes for thyroid between racial and ethnic groups that contribute to disparities. Identifying these differences and their causes are the key to understanding and reducing disparities in presentation and outcomes in endocrine disorders. Evidence Acquisition: The present study reviews original studies identifying and exploring differences between benign and malignant thyroid diseases. A PubMed, Web of Science, and Scopus search was conducted for English-language studies using the terms “thyroid,” “thyroid disease,” “thyroid cancer,” “race,” “ethnicity,” and “disparities” from inception to December 31, 2022. Evidence Synthesis: Many racial and ethnic disparities in the diagnosis, presentation, treatment, and outcomes of thyroid disease were found. Non-White patients are more likely to have a later time to referral, to present with more advanced disease, to have more aggressive forms of thyroid cancer, and are less likely to receive the appropriate treatment than White patients. Overall and disease-specific survival rates are lower in Black and Hispanic populations when compared to White patients. Conclusions: Extensive disparities exist in thyroid disease diagnosis, treatment, and outcomes that may have been overlooked. Further work is needed to identify the causes of these disparities to begin to work toward equity in the care of thyroid disease.

7 August 2020 in Current Treatment Options in Oncology
Verified
Journal Article
Closed access
PDF file
WMWilson Alobuia M.D
Wilson Alobuia M.D
AGAndrea Gillis
Andrea Gillis
EKElectron Kebebew
Electron Kebebew

27 February 2024 in The American Journal of Surgery
Verified
Journal Article
Closed access
HNHayato Nakanishi
Hayato Nakanishi
RWRongzhi Wang
Rongzhi Wang
SMShahid Miangul
Shahid Miangul
GKGrace E. Kim
Grace E. Kim
OSOmotayo A. Segun-Omosehin
Omotayo A. Segun-Omosehin
AGAndrea Gillis
Andrea Gillis

1 November 2024 in Thyroid®
Verified
Journal Article
Closed access
ZSZhixing Song
Zhixing Song
CWChristopher Wu
Christopher Wu
JKJulia Kasmirski
Julia Kasmirski
AGAndrea Gillis
Andrea Gillis
JFJessica Fazendin
Jessica Fazendin
HCHerbert Chen
Herbert Chen
Background: The increased utilization of computed tomography (CT) has led to a higher detection rate of thyroid incidentalomas. Currently, there are no widely agreed-upon guidelines for managing these incidentalomas. This study aims to investigate the prevalence, follow-up practices, and malignancy rates of thyroid incidentalomas detected by CT. Methods: We conducted a comprehensive search of PubMed, Embase, and Cochrane databases to identify relevant studies published before April 12, 2024 (PROSPERO #42024535501). Studies reporting on the prevalence, follow-up, and risk of malignancy (ROM) of thyroid incidentalomas detected by CT were included. Combined outcomes were analyzed using pooled proportion with a random-effects model. The risk of bias was assessed using the Cochrane risk-of-bias tool for randomized trials (RoB 2) and the Newcastle–Ottawa Scale tool. Subgroup analyses were conducted based on characteristics including size of the incidentaloma, CT area, and age of the study population. Results: Thirty-eight studies involving 195,959 patients were included in the prevalence analysis, revealing a prevalence of thyroid incidentalomas on CT of 8.3% (confidence interval [CI], 7.4–9.3). The prevalence was higher in neck CT (16.5%, CI, 11.0–22.1) compared with chest CT (6.6%, CI, 5.3–7.9). Multiple incidentalomas were found in 27.0% (CI, 12.9–41.1) of patients. Of the nodules, 46.3% (CI, 32.3–60.3) were ≥1 cm, and 28.6% (CI, 19.9–37.3) were ≥1.5 cm. Thyroid ultrasounds, biopsies, and surgeries were performed in 34.9% (CI, 26.1–43.7), 28.4% (CI, 19.9–36.9), and 8.2% (CI, 2.1–14.4) of cases, respectively. Additionally, 25 studies with 6272 patients reported a ROM of 3.9% (CI, 3.0–4.9) for thyroid incidentalomas detected on CT. A higher ROM was observed in incidentalomas ≥1 cm (11.7%, CI, 3.9–19.4) and ≥1.5 cm (24.9%, CI, 0–52.7) compared with those <1 cm (0.1%, CI, 0–0.8) and <1.5 cm (0%, CI, 0–0.2). Conclusions: Most thyroid incidentalomas identified on CT are benign. Implementing a collaborative protocol between radiologists and thyroid specialists to manage high-risk thyroid incidentalomas can ensure appropriate follow-up and optimal patient care.

4 November 2022 in The American Journal of Surgery
Verified
Journal Article
Closed access
AGAndrea Gillis
Andrea Gillis
PZPolina Zmijewski
Polina Zmijewski
BCBritney Corey
Britney Corey
JFJessica Fazendin
Jessica Fazendin
HCHerbert Chen
Herbert Chen
SDSophie Dream
Sophie Dream

24 November 2023 in The Oncologist
Verified
Journal Article
Open access
PDF file
RWRongzhi Wang
Rongzhi Wang
RRRhiannon D Reed
Rhiannon D Reed
GPGriffin Price
Griffin Price
PAPeter Abraham
Peter Abraham
MLMarshall Lewis
Marshall Lewis
JFJessica Fazendin
Jessica Fazendin
Hyperparathyroidism (HPT) and malignancy are the most common causes of hypercalcemia. Among kidney transplant (KT) recipients, hypercalcemia is mostly caused by tertiary HPT. Persistent tertiary HPT after KT is associated with allograft failure. Previous studies on managing tHPT were subjected to survivor treatment selection bias; as such, the impact of tertiary HPT treatment on allograft function remained unclear. We aim to assess the association between hypercalcemic tertiary HPT treatment and kidney allograft survival. We identified 280 KT recipients (2015-2019) with elevated post-KT adjusted serum calcium and parathyroid hormone (PTH). KT recipients were characterized by treatment: cinacalcet, parathyroidectomy, or no treatment. Time-varying Cox regression with delayed entry at the time of first elevated post-KT calcium was conducted, and death-censored and all-cause allograft failure were compared by treatment groups. Of the 280 recipients with tHPT, 49 underwent PTx, and 98 received cinacalcet. The median time from KT to first elevated calcium was 1 month (IQR: 0-4). The median time from first elevated calcium to receiving cinacalcet and parathyroidectomy was 0(IQR: 0-3) and 13(IQR: 8-23) months, respectively. KT recipients with no treatment had shorter dialysis vintage (P = .017) and lower PTH at KT (P = .002), later onset of hypercalcemia post-KT (P < .001). Treatment with PTx (adjusted hazard ratio (aHR) = 0.18, 95%CI 0.04-0.76, P = .02) or cinacalcet (aHR = 0.14, 95%CI 0.004-0.47, P = .002) was associated with lower risk of death-censored allograft failure. Moreover, receipt of PTx (aHR = 0.28, 95%CI 0.12-0.66, P < .001) or cinacalcet (aHR = 0.38, 95%CI 0.22-0.66, P < .001) was associated with lower risk of all-cause allograft failure. This study demonstrates that treatment of hypercalcemic tertiary HPT post-KT is associated with improved allograft survival. Although these findings are not specific to hypercalcemia of malignancy, they do demonstrate the negative impact of hypercalcemic tertiary HPT on kidney function. Hypercalcemic HPT should be screened and aggressively treated post-KT.